Cargando…
Secukinumab: A Review in Psoriatic Arthritis
Secukinumab (Cosentyx(®)) is a fully human monoclonal antibody that selectively targets interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriatic arthritis (PsA). Administered subcutaneously, the first-in-class anti-IL-17 agent is approved in numerous countries world...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049904/ https://www.ncbi.nlm.nih.gov/pubmed/33661486 http://dx.doi.org/10.1007/s40265-021-01476-3 |